REDEMPLO

all catalysts(0)

nothing on the calendar yet

News(5)

• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 4d ago
• FDA panel confronting peptide controversy
  Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
  stat · 19d ago
• Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
  To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
  biopharma_dive · 20d ago
• Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
  Arrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer R…
  endpoints · 20d ago
• Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
  With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
  biospace · 20d ago